![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA APPROVES INJECTION TO COUNTER NERVE AGENTS FOR CIVILIANS
FDA APPROVES INJECTION TO COUNTER NERVE AGENTS FOR CIVILIANS
October 2, 2006
The FDA has approved Duodote (atropine and pralidoxime chloride injection) for use by trained emergency medical services personnel to treat civilians exposed to life-threatening organophosphorus-containing nerve agents, such as sarin, and insecticides. Duodote is manufactured by Meridian Medical Technologies.
The FDA previously approved atropine and pralidoxime chloride injection under the name Antidote Treatment -- Nerve Agent Auto-Injector (ATNAA) for military use. Developed by the U.S. Army and manufactured by Meridian, ATNAA is not available for use in civilians. The drug was approved in 2002.
"Today's approval facilitates the stockpiling of the product so that it can be used to treat civilians in an emergency," said Douglas Throckmorton, deputy director of FDA's Center for Drug Evaluation and Research. The manufacturer will distribute Duodote directly to emergency medical service organizations or their suppliers.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct